Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Enterprise Value (2016 - 2025)

Celldex Therapeutics has reported Enterprise Value over the past 16 years, most recently at -$518.6 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$518.6 million for Q4 2025, up 28.5% from a year ago — trailing twelve months through Dec 2025 was -$518.6 million (up 28.5% YoY), and the annual figure for FY2025 was -$518.6 million, up 28.5%.
  • Enterprise Value for Q4 2025 was -$518.6 million at Celldex Therapeutics, up from -$583.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for CLDX hit a ceiling of -$164.0 million in Q2 2021 and a floor of -$823.8 million in Q1 2024.
  • Median Enterprise Value over the past 5 years was -$415.7 million (2021), compared with a mean of -$462.0 million.
  • Biggest five-year swings in Enterprise Value: plummeted 227.77% in 2021 and later grew 29.18% in 2023.
  • Celldex Therapeutics' Enterprise Value stood at -$408.2 million in 2021, then grew by 25.3% to -$305.0 million in 2022, then plummeted by 38.91% to -$423.6 million in 2023, then crashed by 71.22% to -$725.3 million in 2024, then increased by 28.5% to -$518.6 million in 2025.
  • The last three reported values for Enterprise Value were -$518.6 million (Q4 2025), -$583.2 million (Q3 2025), and -$630.3 million (Q2 2025) per Business Quant data.